RosettaCommons/UTexasAptamer huggingface dataset:
Aptamer: no.21
Target: Mammalian translation initiation factor 4A (eIF4A)
Type of nucleic acid: ssRNA
Sequence: 5′GGGAGACAAGAAUAAAACGCUCAAGGGGACCGCGCCCCACAUGUGAGUGAGGCCGAAACAUAGAUUCGACAGGAGGCUCACAACAGGC3′
Sequence length: 88
GC content: 0.5568181818181818
Affinity: Kd: 27 nM
Pool type: 5′-GGGAGACAAGAATAAAACGCTCAA-N40-TTCGACAGGAGGCTCACAACAGGC-3′
Pool random region: 40
Binding buffer/conditions: 20 mM Tris, pH 7.6, 80 mM potassium acetate, 2.5 mM magnesium acetate and 5% glycerol
Buffer type: Tris Buffers
pH: 7.6
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Therapeutic: " The mammalian translation initiation factor 4A (eIF4A) is a prototype member of the DEAD-box RNA helicase family that couples ATPase activity to RNA binding and unwinding. The selected RNAs, therefore, represent a new class of specific inhibitors that are suitable for the analysis of eukaryotic initiation, and which pose a potential therapeutic against malignancies that are caused by aberrant translational control."
Reference (2003, RNA ): Oguro, A., Ohtsu, T., Svitkin, Y. V., Sonenberg, N., & Nakamura, Y. (2003). RNA aptamers to initiation factor 4A helicase hinder cap-dependent translation by blocking ATP hydrolysis. RNA (New York, N.Y.), 9(4), 394–407. https://doi.org/10.1261/rna.2161303
Aptamer: N17
Target: Differentiated pheochromocytoma cells (PC12 cells), Rat
Type of nucleic acid: ssDNA
Sequence: 5′TAATACGACTCACTATAGCAATGGTACGGTACTTCCGGTTGGATGTAAGGTTGGAGGGGGGCAAAAGTGCACGCTACTTTG3′
Sequence length: 81
GC content: 0.4814814814814814
Affinity: Not reported
Pool type: 5′-TAATACGACTCACTATAGCAATGGTACGGTACTTCC-N25-CAAAAGTGCACGCTACTTTG-3′
Pool random region: 25
Binding buffer/conditions: 5 mM of MgCl2 in PBS
Divalent salt: MgCl
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Diagnositic and herapeutic: "Finding single-stranded (ss)DNA aptamers with capability to distinguish differentiated PC12 cells from normal PC12 cells were selected by subtractive systematic evolution of ligands by exponential enrichment (SELEX) method. . This method may be useful in tumor diagnosis and therapy, and studies of cell differentiation. It also can be applied in finding novel proteins if combined with functional cloning."
Reference (2003, J Biotechnol ): Wang, C., Zhang, M., Yang, G., Zhang, D., Ding, H., Wang, H., Fan, M., Shen, B., & Shao, N. (2003). Single-stranded DNA aptamers that bind differentiated but not parental cells: subtractive systematic evolution of ligands by exponential enrichment. Journal of biotechnology, 102(1), 15–22. https://doi.org/10.1016/s0168-1656(02)00360-7
Aptamer: GBI-10
Target: Glioblastoma-derived cell line (U251)
Type of nucleic acid: ssDNA
Sequence: 5′GGCCTGTTGTGAGCCTCCTCCCAGAGGGAAGACTTTAGGTTCGGTTCACGTCCCGCTTATTCTTGTCTCCC3′
Sequence length: 71
GC content: 0.5633802816901409
Affinity: Kd:150 nM
Pool type: 5′-GCCTGTTGTGAGCCTCCT-N34-CGCTTATTCTTGTCTCCC-3′
Pool random region: 34
Binding buffer/conditions: 10 mM Tris·HCl (pH 7.5) containing 150 mM NaCl, 1 mM MgCl2, 1 mM CaCl2, 0.1% (wt/vol) BSA, 0.1% (vol/vol) Triton X-100, and 0.1% (vol/vol) Tween 20
Divalent salt: MgCl/CaCl
Buffer type: Tris Buffers
pH: 7.5
Molecular weight of target: 250 kDa
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Diagnostic and Therapeutic: "This tumor cell SELEX demonstrates the ability to identify known tumor markers, such as tenascin-C. It is likely that complex–target SELEX experiments can discover previously uncharacterized markers for tumors, pathologies, development, and differentiation. Such dissection of complex biological systems by the SELEX process may generate aptamers for diagnostic and therapeutic uses."
Additional information: *constant region and pool type are different in the first nucliotide( constant region in sequence have an extra G base pair)
Reference (2003, Proc Natl Acad Sci U S A ): Daniels, D. A., Chen, H., Hicke, B. J., Swiderek, K. M., & Gold, L. (2003). A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment. Proceedings of the National Academy of Sciences of the United States of America, 100(26), 15416–15421. https://doi.org/10.1073/pnas.2136683100
Aptamer: 10N23−6
Target: ATP (Adenosine triphosphate)
Type of nucleic acid: 5-uracil-modified-RNA
Sequence: 5'CGUGACGUGUGUGUGGGCUGUGGCAGACGUAAGGCUGAGAUUGCCGUCCGUAAUUGAGUGCGGCAGCGAGAGAGAGCAGACUCUCUCUCGUCCUCUUCUC3'
Sequence length: 100
GC content: 0.58
Affinity: Kd: 1.08 μM
Pool type: 5'CGTGACGTGTGTGTGGGCTG-N60-CTCTCTCTCGTCCTCTTCTC3'
Pool random region: 60
Binding buffer/conditions: 100 mM NaCl; 1 mM MgCl2; 20 mM Tris-HCl, pH 7.12
Divalent salt: MgCl
Buffer type: Tris Buffers
pH: 7.12
Molecular weight of target: Not reported
Post-SELEX modifications: The sequence for 10n23-6 was generated from previously identified aptamer 10n23 and was modified by a couple base pairs in the nts 46-78 region.
Application as quoted in the referenced paper: Diagnostic: " The incorporation of a cationic amine into nucleic acids clearly allows novel interactions to occur during the molecular recognition of ligands, which carries interesting implications for the RNA world hypothesis. In addition, new materials generated from such functionalized nucleic acids could be useful tools in research and diagnostics."
Additional information: The aptamer is UNH2 modified. When they are converted to C, the binding affinity decreases. (5-(3-aminopropyl)uridine triphosphate (UNH2)
Reference (2003, Biochemistry ): Vaish, N. K., Larralde, R., Fraley, A. W., Szostak, J. W., & McLaughlin, L. W. (2003). A novel, modification-dependent ATP-binding aptamer selected from an RNA library incorporating a cationic functionality. Biochemistry, 42(29), 8842–8851. https://doi.org/10.1021/bi027354i
Aptamer: Spiegelmer B12b10_65
Target: D‐staphylococcal enterotoxin B peptide (respective SEB peptides)
Type of nucleic acid: ssDNA
Sequence: 5'GACGTCTTCGAATCCCCATACTGTGGCATTGGCTCAGGACGGTCTGGAGGATGGGGCTTGACGTC3'
Sequence length: 65
GC content: 0.5846153846153846
Affinity: Kd: 200 ± 20 nM
Pool type: 5′‐TCAGCTGGACGTCTTCGAAT‐N60‐TGTCAGGAGCTCGAATTCCC‐3′
Pool random region: 60
Binding buffer/conditions: 20 mM Tris, pH 7.4; 250 mM NaCl; 5 mM KCl; 2 mM CaCl2; 1 mM MgCl2; 0.005% Triton X‐100
Divalent salt: MgCl/CaCl
Buffer type: Tris Buffers
pH: 7.4
Molecular weight of target: 28 kDa protein
Post-SELEX modifications: Truncated version of b12b10 (65 nts)
Application as quoted in the referenced paper: Diagnostic: " In order to generate a Spiegelmer with wide application potential for the diagnosis and/or treatment of SEB mediated diseases, we envisaged a domain approach to perform the mirror-image in vitro selection. diagnosis and/or treatment of SEB mediated diseases"
Reference (2003, Nucleic Acids Res ): Purschke, W. G., Radtke, F., Kleinjung, F., & Klussmann, S. (2003). A DNA Spiegelmer to staphylococcal enterotoxin B. Nucleic acids research, 31(12), 3027–3032. https://doi.org/10.1093/nar/gkg413
Aptamer: Spiegelmer B12b10_65
Target: D‐staphylococcal enterotoxin B peptide ( full-length SEB protein)
Type of nucleic acid: ssDNA
Sequence: 5'GACGTCTTCGAATCCCCATACTGTGGCATTGGCTCAGGACGGTCTGGAGGATGGGGCTTGACGTC3'
Sequence length: 65
GC content: 0.5846153846153846
Affinity: Kd: 420 nM
Pool type: 5′‐TCAGCTGGACGTCTTCGAAT‐N60‐TGTCAGGAGCTCGAATTCCC‐3′
Pool random region: 60
Binding buffer/conditions: 20 mM Tris, pH 7.4; 250 mM NaCl; 5 mM KCl; 2 mM CaCl2; 1 mM MgCl2; 0.005% Triton X‐100
Divalent salt: MgCl/CaCl
Buffer type: Tris Buffers
pH: 7.4
Molecular weight of target: 28 kDa protein
Post-SELEX modifications: Truncated version of b12b10 (65 nts)
Application as quoted in the referenced paper: Diagnostic: " In order to generate a Spiegelmer with wide application potential for the diagnosis and/or treatment of SEB mediated diseases, we envisaged a domain approach to perform the mirror-image in vitro selection. diagnosis and/or treatment of SEB mediated diseases"
Reference (2003, Nucleic Acids Res ): Purschke, W. G., Radtke, F., Kleinjung, F., & Klussmann, S. (2003). A DNA Spiegelmer to staphylococcal enterotoxin B. Nucleic acids research, 31(12), 3027–3032. https://doi.org/10.1093/nar/gkg413
Aptamer: M9a-1
Target: Antibody-mediated inhibition of cytotoxic T cell antigen-4 (CTLA-4)
Type of nucleic acid: 2'-fluoro-RNA
Sequence: 5'GGGGGAAUUCUAAUACGACUCACUAUAGGGAGAGAGGAAGAGGGAUAGGGCCGCCCGAGUACAAACGUACUCGCCUGUUUGCCCAACCGACAUAACCCAGAGGUCGAUAGUACUGGAUCCCCCC3'
Sequence length: 124
GC content: 0.5483870967741935
Affinity: Kd: 45 nM
Pool type: 5'-ATCGACCTCTGGGTTATG-N40-CCCATCCCTCTTCCTC-3'
Pool random region: 40
Binding buffer/conditions: Binding buffer for Assay: HEPES wash buffer (20mM HEPES pH 7.4, 0.15M NaCl, 2mM CaCl2)  + 0.01% BSA
Divalent salt: CaCl
Buffer type: Other Buffers
pH: 7.4
Molecular weight of target: Not reported
Application as quoted in the referenced paper: Therapeutic: " Development of RNA aptamers that bind CTLA-4 with high affinity and specificity. These aptamers inhibit CTLA-4 function in vitro and enhance tumor immunity in mice. Moreover, assembly of the aptamers into tetrameric forms significantly enhances their bioactivity in vitro and in vivo. These results demonstrate that aptamers can be used to manipulate the immune system for therapeutic applications and that multivalent versions of aptamers may be particularly potent agents in vivo."
Additional information: The contant region drived from figure 1 is 5'-GGGAGAGAGGAAGAGGGATAGGG-N40-CATAACCCAGAGGTCGATAGTACTGGATCCCCCC-3'
The pool/library in the supplement was reported in pool randon region
DNA library/pool was used as a template to generate the RNA pool used in the selection. A T7 promoter sequence might be necessary to use this DNA library/pool as a template to generate the RNA pool in the selection.
Reference (2003, Cancer Res ): Santulli-Marotto, S., Nair, S. K., Rusconi, C., Sullenger, B., & Gilboa, E. (2003). Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity. Cancer research, 63(21), 7483–7489.
Aptamer: M9a-4
Target: Antibody-mediated inhibition of cytotoxic T cell antigen-4 (CTLA-4)
Type of nucleic acid: 2'-fluoro-RNA
Sequence: 5'GGGGGAAUUCUAAUACGACUCACUAUAGGGAGAGAGGAAGAGGGAUAGGGCAGCCAAAGGAUAUCCAAGCGGCACGCCAUAACACAACACCAUAACCCAGAGGUCGAUAGUACUGGAUCCCCCC3'
Sequence length: 124
GC content: 0.5241935483870968
Affinity: Not reported
Pool type: 5'-ATCGACCTCTGGGTTATG-N40-CCCATCCCTCTTCCTC-3'
Pool random region: 40
Binding buffer/conditions: Binding buffer for Assay: HEPES wash buffer (20mM HEPES pH 7.4, 0.15M NaCl, 2mM CaCl2)  + 0.01% BSA
Divalent salt: CaCl
Buffer type: Other Buffers
pH: 7.4
Molecular weight of target: Not reported
Application as quoted in the referenced paper: Therapeutic: " Development of RNA aptamers that bind CTLA-4 with high affinity and specificity. These aptamers inhibit CTLA-4 function in vitro and enhance tumor immunity in mice. Moreover, assembly of the aptamers into tetrameric forms significantly enhances their bioactivity in vitro and in vivo. These results demonstrate that aptamers can be used to manipulate the immune system for therapeutic applications and that multivalent versions of aptamers may be particularly potent agents in vivo."
Additional information: The contant region drived from figure 1 is 5'-GGGAGAGAGGAAGAGGGATAGGG-N40-CATAACCCAGAGGTCGATAGTACTGGATCCCCCC-3'
The pool/library in the supplement was reported in pool randon region
DNA library/pool was used as a template to generate the RNA pool used in the selection. A T7 promoter sequence might be necessary to use this DNA library/pool as a template to generate the RNA pool in the selection.
Reference (2003, Cancer Res ): Santulli-Marotto, S., Nair, S. K., Rusconi, C., Sullenger, B., & Gilboa, E. (2003). Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity. Cancer research, 63(21), 7483–7489.
Aptamer: M9a-5
Target: Antibody-mediated inhibition of cytotoxic T cell antigen-4 (CTLA-4)
Type of nucleic acid: 2'-fluoro-RNA
Sequence: 5'GGGGGAAUUCUAAUACGACUCACUAUAGGGAGAGAGGAAGAGGGAUAGGGCACCGGAAGGGCUACACUCCUAUAUCCCCUGCCCAGCCCGCCAUAACCCAGAGGUCGAUAGUACUGGAUCCCCCC3'
Sequence length: 125
GC content: 0.568
Affinity: Kd: 40 nM
Pool type: 5'-ATCGACCTCTGGGTTATG-N40-CCCATCCCTCTTCCTC-3'
Pool random region: 40
Binding buffer/conditions: Binding buffer for Assay: HEPES wash buffer (20mM HEPES pH 7.4, 0.15M NaCl, 2mM CaCl2)  + 0.01% BSA
Divalent salt: CaCl
Buffer type: Other Buffers
pH: 7.4
Molecular weight of target: Not reported
Application as quoted in the referenced paper: Therapeutic: " Development of RNA aptamers that bind CTLA-4 with high affinity and specificity. These aptamers inhibit CTLA-4 function in vitro and enhance tumor immunity in mice. Moreover, assembly of the aptamers into tetrameric forms significantly enhances their bioactivity in vitro and in vivo. These results demonstrate that aptamers can be used to manipulate the immune system for therapeutic applications and that multivalent versions of aptamers may be particularly potent agents in vivo."
Additional information: The contant region drived from figure 1 is 5'-GGGAGAGAGGAAGAGGGATAGGG-N40-CATAACCCAGAGGTCGATAGTACTGGATCCCCCC-3'
The pool/library in the supplement was reported in pool randon region
DNA library/pool was used as a template to generate the RNA pool used in the selection. A T7 promoter sequence might be necessary to use this DNA library/pool as a template to generate the RNA pool in the selection.
Reference (2003, Cancer Res ): Santulli-Marotto, S., Nair, S. K., Rusconi, C., Sullenger, B., & Gilboa, E. (2003). Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity. Cancer research, 63(21), 7483–7489.
Aptamer: M9a-8
Target: Antibody-mediated inhibition of cytotoxic T cell antigen-4 (CTLA-4)
Type of nucleic acid: 2'-fluoro-RNA
Sequence: 5'GGGGGAAUUCUAAUACGACUCACUAUAGGGAGAGAGGAAGAGGGAUAGGGACCACAGCCUUUAUCCAAGCGGGUGAGCCCCGUGAACAAUCAUAACCCAGAGGUCGAUAGUACUGGAUCCCCCC3'
Sequence length: 124
GC content: 0.532258064516129
Affinity: Kd: 35 nM
Pool type: 5'-ATCGACCTCTGGGTTATG-N40-CCCATCCCTCTTCCTC-3'
Pool random region: 40
Binding buffer/conditions: Binding buffer for Assay: HEPES wash buffer (20mM HEPES pH 7.4, 0.15M NaCl, 2mM CaCl2)  + 0.01% BSA
Divalent salt: CaCl
Buffer type: Other Buffers
pH: 7.4
Molecular weight of target: Not reported
Application as quoted in the referenced paper: Therapeutic: " Development of RNA aptamers that bind CTLA-4 with high affinity and specificity. These aptamers inhibit CTLA-4 function in vitro and enhance tumor immunity in mice. Moreover, assembly of the aptamers into tetrameric forms significantly enhances their bioactivity in vitro and in vivo. These results demonstrate that aptamers can be used to manipulate the immune system for therapeutic applications and that multivalent versions of aptamers may be particularly potent agents in vivo."
Additional information: The contant region drived from figure 1 is 5'-GGGAGAGAGGAAGAGGGATAGGG-N40-CATAACCCAGAGGTCGATAGTACTGGATCCCCCC-3'
The pool/library in the supplement was reported in pool randon region
DNA library/pool was used as a template to generate the RNA pool used in the selection. A T7 promoter sequence might be necessary to use this DNA library/pool as a template to generate the RNA pool in the selection.
Reference (2003, Cancer Res ): Santulli-Marotto, S., Nair, S. K., Rusconi, C., Sullenger, B., & Gilboa, E. (2003). Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity. Cancer research, 63(21), 7483–7489.
Aptamer: M9a-9
Target: Antibody-mediated inhibition of cytotoxic T cell antigen-4 (CTLA-4)
Type of nucleic acid: 2'-fluoro-RNA
Sequence: 5'GGGGGAAUUCUAAUACGACUCACUAUAGGGAGAGAGGAAGAGGGAUAGGGCCGACGUGCCGCAACUUCAACCCUGCACAACCAAUCCGCCCAUAACCCAGAGGUCGAUAGUACUGGAUCCCCCC3'
Sequence length: 124
GC content: 0.5564516129032258
Affinity: Kd: 10 nM
Pool type: 5'-ATCGACCTCTGGGTTATG-N40-CCCATCCCTCTTCCTC-3'
Pool random region: 40
Binding buffer/conditions: Binding buffer for Assay: HEPES wash buffer (20mM HEPES pH 7.4, 0.15M NaCl, 2mM CaCl2)  + 0.01% BSA
Divalent salt: CaCl
Buffer type: Other Buffers
pH: 7.4
Molecular weight of target: Not reported
Application as quoted in the referenced paper: Therapeutic: " Development of RNA aptamers that bind CTLA-4 with high affinity and specificity. These aptamers inhibit CTLA-4 function in vitro and enhance tumor immunity in mice. Moreover, assembly of the aptamers into tetrameric forms significantly enhances their bioactivity in vitro and in vivo. These results demonstrate that aptamers can be used to manipulate the immune system for therapeutic applications and that multivalent versions of aptamers may be particularly potent agents in vivo."
Additional information: The contant region drived from figure 1 is 5'-GGGAGAGAGGAAGAGGGATAGGG-N40-CATAACCCAGAGGTCGATAGTACTGGATCCCCCC-3'
The pool/library in the supplement was reported in pool randon region
DNA library/pool was used as a template to generate the RNA pool used in the selection. A T7 promoter sequence might be necessary to use this DNA library/pool as a template to generate the RNA pool in the selection.
Reference (2003, Cancer Res ): Santulli-Marotto, S., Nair, S. K., Rusconi, C., Sullenger, B., & Gilboa, E. (2003). Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity. Cancer research, 63(21), 7483–7489.
Aptamer: M9a-14
Target: Antibody-mediated inhibition of cytotoxic T cell antigen-4 (CTLA-4)
Type of nucleic acid: 2'-fluoro-RNA
Sequence: 5'GGGGGAAUUCUAAUACGACUCACUAUAGGGAGAGAGGAAGAGGGAUAGGGCAACGAAAGGUGCUCCACUAAGAAUGGAACUUCUGCGAUCCAUAACCCAGAGGUCGAUAGUACUGGAUCCCCCC3'
Sequence length: 124
GC content: 0.5080645161290323
Affinity: Kd: 25 nM
Pool type: 5'-ATCGACCTCTGGGTTATG-N40-CCCATCCCTCTTCCTC-3'
Pool random region: 40
Binding buffer/conditions: Binding buffer for Assay: HEPES wash buffer (20mM HEPES pH 7.4, 0.15M NaCl, 2mM CaCl2)  + 0.01% BSA
Divalent salt: CaCl
Buffer type: Other Buffers
pH: 7.4
Molecular weight of target: Not reported
Application as quoted in the referenced paper: Therapeutic: " Development of RNA aptamers that bind CTLA-4 with high affinity and specificity. These aptamers inhibit CTLA-4 function in vitro and enhance tumor immunity in mice. Moreover, assembly of the aptamers into tetrameric forms significantly enhances their bioactivity in vitro and in vivo. These results demonstrate that aptamers can be used to manipulate the immune system for therapeutic applications and that multivalent versions of aptamers may be particularly potent agents in vivo."
Additional information: The contant region drived from figure 1 is 5'-GGGAGAGAGGAAGAGGGATAGGG-N40-CATAACCCAGAGGTCGATAGTACTGGATCCCCCC-3'
The pool/library in the supplement was reported in pool randon region
DNA library/pool was used as a template to generate the RNA pool used in the selection. A T7 promoter sequence might be necessary to use this DNA library/pool as a template to generate the RNA pool in the selection.
Reference (2003, Cancer Res ): Santulli-Marotto, S., Nair, S. K., Rusconi, C., Sullenger, B., & Gilboa, E. (2003). Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity. Cancer research, 63(21), 7483–7489.
Aptamer: M9a-15
Target: Antibody-mediated inhibition of cytotoxic T cell antigen-4 (CTLA-4)
Type of nucleic acid: 2'-fluoro-RNA
Sequence: 5'GGGGGAAUUCUAAUACGACUCACUAUAGGGAGAGAGGAAGAGGGAUAGGGGUGCUCAAUCACGAACCCGCUCGACUUCUUCUCCCAAGCCCAUAACCCAGAGGUCGAUAGUACUGGAUCCCCCC3'
Sequence length: 124
GC content: 0.5403225806451613
Affinity: Kd: 70 nM
Pool type: 5'-ATCGACCTCTGGGTTATG-N40-CCCATCCCTCTTCCTC-3'
Pool random region: 40
Binding buffer/conditions: Binding buffer for Assay: HEPES wash buffer (20mM HEPES pH 7.4, 0.15M NaCl, 2mM CaCl2)  + 0.01% BSA
Divalent salt: CaCl
Buffer type: Other Buffers
pH: 7.4
Molecular weight of target: Not reported
Application as quoted in the referenced paper: Therapeutic: " Development of RNA aptamers that bind CTLA-4 with high affinity and specificity. These aptamers inhibit CTLA-4 function in vitro and enhance tumor immunity in mice. Moreover, assembly of the aptamers into tetrameric forms significantly enhances their bioactivity in vitro and in vivo. These results demonstrate that aptamers can be used to manipulate the immune system for therapeutic applications and that multivalent versions of aptamers may be particularly potent agents in vivo."
Additional information: The contant region drived from figure 1 is 5'-GGGAGAGAGGAAGAGGGATAGGG-N40-CATAACCCAGAGGTCGATAGTACTGGATCCCCCC-3'
The pool/library in the supplement was reported in pool randon region
DNA library/pool was used as a template to generate the RNA pool used in the selection. A T7 promoter sequence might be necessary to use this DNA library/pool as a template to generate the RNA pool in the selection.
Reference (2003, Cancer Res ): Santulli-Marotto, S., Nair, S. K., Rusconi, C., Sullenger, B., & Gilboa, E. (2003). Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity. Cancer research, 63(21), 7483–7489.
Aptamer: M9a-18
Target: Antibody-mediated inhibition of cytotoxic T cell antigen-4 (CTLA-4)
Type of nucleic acid: 2'-fluoro-RNA
Sequence: 5'GGGGGAAUUCUAAUACGACUCACUAUAGGGAGAGAGGAAGAGGGAUAGGGUGCUCCAACACUCACUUCGGAACCACCUGCAUUCCGCUCUCAUAACCCAGAGGUCGAUAGUACUGGAUCCCCCC3'
Sequence length: 124
GC content: 0.532258064516129
Affinity: Not reported
Pool type: 5'-ATCGACCTCTGGGTTATG-N40-CCCATCCCTCTTCCTC-3'
Pool random region: 40
Binding buffer/conditions: Binding buffer for Assay: HEPES wash buffer (20mM HEPES pH 7.4, 0.15M NaCl, 2mM CaCl2)  + 0.01% BSA
Divalent salt: CaCl
Buffer type: Other Buffers
pH: 7.4
Molecular weight of target: Not reported
Application as quoted in the referenced paper: Therapeutic: " Development of RNA aptamers that bind CTLA-4 with high affinity and specificity. These aptamers inhibit CTLA-4 function in vitro and enhance tumor immunity in mice. Moreover, assembly of the aptamers into tetrameric forms significantly enhances their bioactivity in vitro and in vivo. These results demonstrate that aptamers can be used to manipulate the immune system for therapeutic applications and that multivalent versions of aptamers may be particularly potent agents in vivo."
Additional information: The contant region drived from figure 1 is 5'-GGGAGAGAGGAAGAGGGATAGGG-N40-CATAACCCAGAGGTCGATAGTACTGGATCCCCCC-3'
The pool/library in the supplement was reported in pool randon region
DNA library/pool was used as a template to generate the RNA pool used in the selection. A T7 promoter sequence might be necessary to use this DNA library/pool as a template to generate the RNA pool in the selection.
Reference (2003, Cancer Res ): Santulli-Marotto, S., Nair, S. K., Rusconi, C., Sullenger, B., & Gilboa, E. (2003). Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity. Cancer research, 63(21), 7483–7489.